NRD
SRPT icon

Nebula Research & Development’s Sarepta Therapeutics SRPT Stock Holding History

Nebula Research & Development’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-98,075
Closed -$1.68M – 767
2025
Q2 		$1.68M Buy
+98,075
New +$4.18M 0.14% 234
2024
Q2 		– Sell
-3,378
Closed -$437K – 1030
2024
Q1 		$437K Buy
+3,378
New +$414K 0.09% 406

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Nebula Research & Development's SRPT Position: Q3 2025 in Review

Nebula Research & Development sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 98,075 shares — an estimated $1.68M sold.

Nebula Research & Development first reported a position in SRPT in Q1 2024 and held it in 2 quarters. The position peaked at $1.68M in Q2 2025. 320 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Nebula Research & Development reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 98,075 Sarepta Therapeutics shares in Q3 2025, an estimated $1.68M.
  • Nebula Research & Development first reported a position in Sarepta Therapeutics in Q1 2024 and held it in 2 quarters.
  • Nebula Research & Development's Sarepta Therapeutics position peaked at $1.68M in Q2 2025.
  • 320 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.